This is a preview of subscription content, log in via an institution to check access.
References
Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of its ethyl ester prodrug, GS4104. Pharmacologist 1997; 39 (1): 23
Cundy KC, Eisenberg G, Bidgood A, et al. Enhanced delivery of the novel influenza neuraminidase inhibitor GS4071 to rat lung after oral administration of the prodrug GS4104 [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 25
Wood ND, Aitken M, Sharp S, et al. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro 64-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 25
Oral influenza compound reduced symptoms and prevented illness in humans; phase II data. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto 5. Roche/Gilead GS4104 oral flu pill reduces duration of disease by 30%. FDC Rep Pink Sheet 1998 Oct 5; 60: 14
He G, Massarella J, Aitken M, et al. The pharmacokinetics and safety of the oral neuraminidase inhibitor RO 64-0796/GS4104 when administered concurrently with cimetidine or probenecid in healthy subjects. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 44
Gilead Sciences announces discovery of orally active influenza inhibitors [press release]. Gilead Sciences [online]: 1996; 17 Sep. Available from: URL: http://www.gilead.com [Accessed 1999 Aug 30]
Hoffmann-La Roche and Gilead Sciences initiate human testing of oral influenza drug GS 4104 [press release]. Gilead Sciences [online]: 1997; 11 Mar. Available from: URL: http://www.gilead.com [Accessed 1999 Aug 30]
Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998 Mar; 42: 640–6
Sidwell RW, Bailey KW, Wong MH, et al. Lack of in vivo development of influenza A virus resistance to the orally effective neuroaminidase inhibitor GS4104. Antiviral Res 1998 Mar; 37: 71
Hayden FG, Lobo M, Treanor JJ, et al. Efficacy and tolerability of oral GS4104 for early treatment of experimental influenza in humans. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Program Addendum; 1997 Sep 28–Oct 1; Toronto, 14
Treanor JJ, Vrooman PS, Hayden FG, et al. Efficacy of oral GS4104 in treating acute influenza [abstract]. 38th Interscience Conference onAntimicrobial Agents andChemotherapy (late-breaker abstracts); 1998 Sep 24–27; San Diego, 21
Aoki F, Osterhaus A, Rimmelzwaan G, et al. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza [abstarct]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (late-breaker abstracts); 1998 Sep 24–27; San Diego, 22
Nicholson KG, Ward P, Kinnersley N, et al. Oral GS4104 in the treatment of influenza in adults is effective and reduces influenza-related complications and need for antibiotic treatment. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 41
Jefferson T, Wegmüller Y, Barker C, et al. The impact of influenza on the workplace and the effect of the antiviral GS4104 on daily performance and work absenteeism. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 46
Hayden FG, Atmar R, Schilling M, et al. Safety and efficacy of oralGS4104 in longtermprophylaxis of natural influenza [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (late-breaker abstracts); 1998 Sep 24–27; San Diego, 22
Rights and permissions
About this article
Cite this article
Oseltamivir. Drugs R&D 2, 173–177 (1999). https://doi.org/10.2165/00126839-199902030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902030-00004